MidWest Drug Development Conference
Downtown Capitol District, Omaha, Neb. | Sept. 30-Oct. 1, 2019
2019-09-30 08:00:00
Register
Downloads
  • Pamphlet
  • Promotional Flyer
  • Map & Other Info
  • Program
  • Home
  • Schedule
  • Venue
  • Technologies
    • By category
      • Autoimmue/Inflammatory
      • Cancer
      • Cardiovascular/Renal
      • Central Nervous System
      • Drug Delivery
      • Infectious Diseases
      • Metabolic
      • Ophthalmology
      • Startups
    • By institution
      • Cincinnati Children’s
      • Colorado
      • Iowa
      • Kansas
      • Kansas St.
      • Kentucky
      • Mayo Clinic
      • Missouri
      • Missouri-KC
      • Nebraska
      • Notre Dame
      • Ohio State
      • Oklahoma
      • Purdue
      • South Dakota
      • Toldeo
      • Wisconsin
    • Startups
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • By category
      • Autoimmue/Inflammatory
      • Cancer
      • Cardiovascular/Renal
      • Central Nervous System
      • Drug Delivery
      • Infectious Diseases
      • Metabolic
      • Ophthalmology
      • Startups
    • By institution
      • Cincinnati Children’s
      • Colorado
      • Iowa
      • Kansas
      • Kansas St.
      • Kentucky
      • Mayo Clinic
      • Missouri
      • Missouri-KC
      • Nebraska
      • Notre Dame
      • Ohio State
      • Oklahoma
      • Purdue
      • South Dakota
      • Toldeo
      • Wisconsin
    • Startups
  • Sponsors
  • News
  • Contact

Bacterial glycosyltransferase inhibitors work as anti-virulence compounds

Kansas State University

NleB1 is an important virulence factor expressed by multiple bacteria including enterohemorrhagic Escherichia coli (EHEC), enteropathogenic E. coli (EPEC), and Salmonella enterica. These bacteria are of significance to human health as they all cause infectious diarrhea. EHEC causes hemorrhagic colitis and hemolytic uremic syndrome. Researchers at Kansas State University, in collaboration with researchers at University of Kansas, have characterized the NleB1 glycosyltransferase because of its proven importance to human E. coli infections. They have since shown that inhibiting NleB1 activity may be efficacious in preventing and treating bacterial infections. Two NleB1 inhibitors were identified using an optimized high-throughput screening (HTS) assay. These compounds do not inhibit the mammalian glycosyltransferase OGT. These NleB1 inhibitors may have utility as anti-virulence compounds.

Advantages

  • Toxicity: Non-toxic to mammalian cells
  • Inhibition: Do not inhibit the mammalian glycosyltransferase OGT
  • Treatment: Have utility in preventing and treating E. coli and Salmonella infections

Applications

  • Bacterial infections
  • Hemorrhagic colitis
  • Hemolytic uremic syndrome

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
Downtown Capitol District, Omaha, NE
Sept. 30-Oct. 1, 2019

Latest News
  • MidWest Drug Development Conference hits the mark again November 18, 2019
  • Limited discount codes remain for industry, investors August 28, 2019
  • Last chance for discounted room rate, offer expires Friday August 27, 2019
  • Special room rate available for early birds July 15, 2019
Twitter Hightlights
  • Big shout out to our contracts specialist Jeff Andersen, who recently won a Golden Stopwatch Award from @Addgene. W… https://t.co/zUt6gttkdx
    about 5 hours ago
  • RT @charlielitton: Important editorial from @OWHopinion re: the critical importance of @InvestNebraska & the need for more #startup support…
    3 days ago